MediWound's EscharEx Phase III VALUE Study To Continue Without Modification Following DSMB Review
MediWound (MDWD) reported that a DSMB review recommended continuing the Phase III VALUE study of EscharEx for venous leg ulcers without modifications, citing no safety concerns. The trial aims to enroll 216 patients, with completion expected by Q1 2027. MDWD's stock closed at $13.11 on September 11, 2026, and is up 2.21% in pre-market trading.
How this was made
The 30-second read
Why it matters
The DSMB's clean safety review removes a major regulatory hurdle, keeping the trial on schedule and preserving investor confidence.
Market read
A small‑cap biotech receives a safety green light, which may modestly lift its stock ahead of upcoming enrollment milestones.
What to watch
Potential enrollment delays or future safety signals could alter the trial timeline.
Background
MediWound Ltd. is conducting a global Phase III trial of its bromelain‑based wound debridement therapy, EscharEx, for venous leg ulcers.
Ticker impact
DSMB review cleared the Phase III VALUE study to continue without modification, confirming safety and allowing enrollment to finish as planned.
Modest upside as investors price in continued trial progress.
The trial remains on track; no new data but safety clearance is a favorable catalyst for a small-cap biotech.
Market effects
Reinforces confidence in wound‑care biotech sector and may buoy peer companies developing similar therapies.
Limited to markets where MediWound trades; no broad regional effect.
Minimal global impact; primarily relevant to investors in small‑cap biotech.
Counterpoint
The lack of new efficacy data means the trial could still face setbacks; caution against over‑optimism.
Key entities
- CompanyMediWound Ltd.
Biotech firm developing EscharEx for chronic wound care.
- ExecutiveOfer Gonen
Chief Executive Officer of MediWound.
